Peptides have emerged as a beacon of hope in drug discovery, particularly for targeting elusive protein-protein interactions (PPIs) that traditional small molecules and biologics struggle to address. These synthetic mini-proteins, especially hydrocarbon-stapled α-helical peptides, are designed to mimic natural proteins while offering enhanced stability and bioactivity. However, despite their promise, there are notable drawbacks that warrant consideration.
One significant drawback is their limited oral bioavailability. Unlike small-molecule drugs that can be easily absorbed through the gastrointestinal tract due to their smaller size and simpler structures, peptides often face challenges when it comes to crossing cell membranes or surviving enzymatic degradation in the digestive system. This limitation typically necessitates alternative delivery methods such as injections—an inconvenience for patients who prefer oral medications.
Moreover, while stapled peptides may excel at inhibiting PPIs within cells where many diseases originate, they still grapple with issues related to specificity and potential off-target effects. The complexity of biological systems means that even slight variations in peptide structure can lead to unintended interactions with other proteins or pathways—a risk not just for efficacy but also for safety.
Additionally, synthesizing these peptides can be resource-intensive and costly compared to traditional pharmaceuticals. The intricate processes involved in creating stable conformations require advanced techniques from synthetic chemistry which might limit accessibility for broader applications.
Finally, there's an ongoing debate about immunogenicity—the potential for these foreign substances introduced into the body to provoke an immune response. While this concern isn't unique to peptides alone—it applies across various therapeutic modalities—it's crucial given how sensitive our immune systems can be.
In summary, while stapled peptides represent a groundbreaking approach in tackling previously 'undruggable' targets within cellular environments—and hold great promise—they come with inherent limitations including poor oral bioavailability, possible off-target effects due to structural complexities, high production costs, and concerns regarding immunogenicity.